Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

NASDAQ:TNXP - Nasdaq - US8902608475 - Common Stock

0.2389  +0 (+1.44%)

After market: 0.2348 0 (-1.72%)

Fundamental Rating

2

Overall TNXP gets a fundamental rating of 2 out of 10. We evaluated TNXP against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of TNXP have multiple concerns. TNXP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TNXP has reported negative net income.
In the past year TNXP has reported a negative cash flow from operations.
In the past 5 years TNXP always reported negative net income.
TNXP had a negative operating cash flow in each of the past 5 years.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -142.38%, TNXP is doing worse than 83.72% of the companies in the same industry.
Looking at the Return On Equity, with a value of -182.25%, TNXP is doing worse than 67.79% of the companies in the same industry.
Industry RankSector Rank
ROA -142.38%
ROE -182.25%
ROIC N/A
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

With a decent Gross Margin value of 20.74%, TNXP is doing good in the industry, outperforming 74.51% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for TNXP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

3

2. Health

2.1 Basic Checks

TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNXP has less shares outstanding than it did 1 year ago.
The number of shares outstanding for TNXP has been increased compared to 5 years ago.
The debt/assets ratio for TNXP is higher compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

TNXP has an Altman-Z score of -11.48. This is a bad value and indicates that TNXP is not financially healthy and even has some risk of bankruptcy.
TNXP has a worse Altman-Z score (-11.48) than 77.52% of its industry peers.
TNXP has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.07, TNXP is not doing good in the industry: 64.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -11.48
ROIC/WACCN/A
WACC10.93%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.33 indicates that TNXP has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.33, TNXP is doing worse than 60.35% of the companies in the same industry.
A Quick Ratio of 2.78 indicates that TNXP has no problem at all paying its short term obligations.
TNXP has a worse Quick ratio (2.78) than 66.02% of its industry peers.
Industry RankSector Rank
Current Ratio 3.33
Quick Ratio 2.78
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.35% over the past year.
Looking at the last year, TNXP shows a very strong growth in Revenue. The Revenue has grown by 182.98%.
EPS 1Y (TTM)85.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%

3.2 Future

Based on estimates for the next years, TNXP will show a very strong growth in Earnings Per Share. The EPS will grow by 25.93% on average per year.
The Revenue is expected to grow by 74.72% on average over the next years. This is a very strong growth
EPS Next Y94.78%
EPS Next 2Y38.44%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue Next Year63.62%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -5M -10M -15M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30 -40 -50

4.3 Compensation for Growth

TNXP's earnings are expected to grow with 25.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.44%
EPS Next 3Y25.93%

More info and screens

0

5. Dividend

5.1 Amount

TNXP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (1/21/2025, 8:00:02 PM)

After market: 0.2348 0 (-1.72%)

0.2389

+0 (+1.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners0.29%
Inst Owner Change6.06%
Ins Owners0%
Ins Owner Change0%
Market Cap44.65M
Analysts82.5
Price Target5.95 (2390.58%)
Short Float %4.17%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-192.57%
Min EPS beat(2)-477.45%
Max EPS beat(2)92.31%
EPS beat(4)3
Avg EPS beat(4)-70.42%
Min EPS beat(4)-477.45%
Max EPS beat(4)92.31%
EPS beat(8)5
Avg EPS beat(8)-33.3%
EPS beat(12)7
Avg EPS beat(12)-19.58%
EPS beat(16)8
Avg EPS beat(16)-16.63%
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-38.15%
Max Revenue beat(2)-10.27%
Revenue beat(4)0
Avg Revenue beat(4)-21.93%
Min Revenue beat(4)-38.15%
Max Revenue beat(4)-3.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-72.22%
PT rev (3m)-72.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-89.17%
EPS NY rev (1m)0%
EPS NY rev (3m)7.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-60.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.95
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-52.79
EYN/A
EPS(NY)-23.03
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.06
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.38%
ROE -182.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.74%
FCFM N/A
ROA(3y)-55.21%
ROA(5y)-86.34%
ROE(3y)-69.72%
ROE(5y)-119.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.19%
Cap/Sales 4.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.33
Quick Ratio 2.78
Altman-Z -11.48
F-Score4
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)24885.3%
Cap/Depr(5y)20651.2%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
EPS Next Y94.78%
EPS Next 2Y38.44%
EPS Next 3Y25.93%
EPS Next 5YN/A
Revenue 1Y (TTM)182.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-29.26%
Revenue Next Year63.62%
Revenue Next 2Y42.72%
Revenue Next 3Y74.72%
Revenue Next 5YN/A
EBIT growth 1Y33.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.1%
OCF growth 3YN/A
OCF growth 5YN/A